Simplicity Wealth LLC Buys 1,766 Shares of Amgen Inc. $AMGN

Simplicity Wealth LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 16.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,305 shares of the medical research company’s stock after purchasing an additional 1,766 shares during the period. Simplicity Wealth LLC’s holdings in Amgen were worth $5,187,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Carolina Wealth Advisors LLC increased its holdings in Amgen by 1.2% during the third quarter. Carolina Wealth Advisors LLC now owns 13,167 shares of the medical research company’s stock worth $5,550,000 after buying an additional 157 shares during the last quarter. Grace & White Inc. NY bought a new stake in Amgen during the third quarter worth $587,000. Gibbs Wealth Management acquired a new stake in Amgen in the third quarter valued at $275,000. James J. Burns & Company LLC lifted its stake in Amgen by 9.7% in the third quarter. James J. Burns & Company LLC now owns 633 shares of the medical research company’s stock valued at $267,000 after acquiring an additional 56 shares during the last quarter. Finally, Winthrop Advisory Group LLC grew its position in shares of Amgen by 31.9% in the 3rd quarter. Winthrop Advisory Group LLC now owns 1,388 shares of the medical research company’s stock valued at $585,000 after acquiring an additional 336 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $439.26 on Friday. The firm has a market cap of $237.48 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 3.22 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $450.98. The business’s 50 day moving average is $417.70 and its 200-day moving average is $377.83.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts predict that Amgen Inc. will post 22.96 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AMGN shares. UBS Group boosted their price objective on shares of Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. Wells Fargo & Company cut their target price on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a research note on Monday, October 12th. Morgan Stanley reduced their price target on Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a report on Wednesday, October 7th. Bank of America boosted their price target on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Finally, Canaccord Genuity Group upped their price objective on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $389.71.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last three months. Insiders own 0.85% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
• Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
• Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
• Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.